Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy, Hormone, Biologic therapy.

Stanford University, Stanford, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Stanford, CA
Treatments:Chemotherapy, Hormone, Biologic therapyHospital:Stanford University
Drugs:Journal:Link
Date:Jul 2013

Description:

Patients:
This study involved 39 peripheral T-cell lymphoma (PTCL) and natural killer (NK) cell lymphoma patients with a median age of 60 years; 72% were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab and the chemotherapy regimen known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).

Toxicities:
There was one death during the study due to heart failure that may have been due to treatment. Treatment-related grade 2-4 heart problems were reported in six patients. Grade 4 neutropenia was also reported.

Results:
The median overall survival was 22 months.

Support:
One of the authors is employed by Genentech, makers of bevacizumab.

Correspondence: Dr. Kristen N. Ganjoo; email: [email protected]



Back